The Role of Radiotherapy Among Patients With Prostate Ductal Adenocarcinoma

Patel, Mausam; Bimali, Milan; Howie, Cole M.; McClain, Paula; Mehta, Saurabh; Harari, Moises; Hans, Harliv Singh; Agarwal, Amit Kumar; Pederson, Aaron; Maraboyina, Sanjay; Kim, Thomas

doi:10.1016/j.clgc.2020.07.004

Cited by 3 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[1,21] Other studies have shown that radiotherapy can effectively reduce the risk of death in DAP patients without lymph node or distant metastases, and cancerspecific mortality is similar to that of patients undergoing radical surgery. [3,22] Importantly, compared with AAP, DAP is more invasive, has a shorter progression-free survival and a higher cancer-specific mortality, regardless of metastasis status or surgery. [5,21,[23][24][25] Therefore, patients with DAP should be advised to receive multimodal comprehensive treatment.…”

Section: Discussionmentioning

confidence: 99%

“…Studies have shown that surgical treatment can achieve a longer survival time than radiotherapy or systemic chemotherapy, especially in patients with non-metastatic DAP [1,21] . Other studies have shown that radiotherapy can effectively reduce the risk of death in DAP patients without lymph node or distant metastases, and cancer-specific mortality is similar to that of patients undergoing radical surgery [3,22] . Importantly, compared with AAP, DAP is more invasive, has a shorter progression-free survival time and a higher cancer-specific mortality, regardless of metastasis status or surgery [5,21,23–25] .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Ductal adenocarcinoma of the prostate or seminal vesicle adenocarcinoma: An multi-disciplinary team (MDT) case report and literature review

Hao

Song

et al. 2022

Current Urology

View full text Add to dashboard Cite

We introduced a 61-year-old male with ductal adenocarcinoma of the prostate who underwent a tortuous diagnosis and treatment. Multi-disciplinary team meetings organized by our hospital have shown great value in the whole process. The patient presented with gross hematuria accompanied by frequent urination initially, and was diagnosed with ductal adenocarcinoma of the prostate involving right seminal vesicle gland and urethra by urethroscopy biopsy. The clinical stage of tumor was T3bN0M0. After 4 cycles of neoadjuvant chemotherapy, the tumor shrank significantly and the patient underwent a laparoscopic radical prostatectomy. But the patient declined to continue chemotherapy postoperatively. After 10 months, the serum prostatic specific antigen increased to 0.05 ng/mL, and multiple metastases were found in the patient's bilateral lungs. However, an unexpected diagnosis of seminal vesicle adenocarcinoma was put forward from another hospital after supplementary pathologic immunohistochemical examination. Then, after careful discussion and demonstration by our multi-disciplinary team experts, we insisted on the diagnosis of ductal adenocarcinoma of the prostate and suggested that the original regimen of chemotherapy should be continued. Up-to-date, 14 months after the operation, the patient continues to survive while undergoing ongoing active treatment as recommended.

show abstract